Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.

Tytuł:
Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
Autorzy:
Patel KV; Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (K.V.P., J.D.B., A.P.).; Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, TX (K.V.P.).
Bahnson JL; Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC (J.L.B., S.A.G.).
Gaussoin SA; Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC (J.L.B., S.A.G.).
Johnson KC; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (K.C.J.).
Pi-Sunyer X; New York Obesity Research Center, Columbia University Medical Center (X.P.).
White U; Pennington Biomedical Research Center, Louisiana State University, Baton Rouge (U.W.).
Olson KL; Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI (K.L.O.).
Bertoni AG; Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (A.G.B.).
Kitzman DW; Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.).
Berry JD; Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (K.V.P., J.D.B., A.P.).
Pandey A; Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (K.V.P., J.D.B., A.P.).
Corporate Authors:
Look AHEAD Research Group
Źródło:
Circulation [Circulation] 2020 Dec 22; Vol. 142 (25), pp. 2420-2430. Date of Electronic Publication: 2020 Nov 09.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Język:
English
Imprint Name(s):
Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [Dallas, Tex., etc., American Heart Association, etc.]
MeSH Terms:
Body Composition*
Diabetes Mellitus, Type 2/*epidemiology
Heart Failure/*epidemiology
Myocardial Infarction/*epidemiology
Adiposity ; Aged ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/physiopathology ; Diabetes Mellitus, Type 2/therapy ; Exercise ; Female ; Healthy Lifestyle ; Heart Disease Risk Factors ; Heart Failure/diagnosis ; Heart Failure/physiopathology ; Heart Failure/prevention & control ; Humans ; Incidence ; Male ; Middle Aged ; Myocardial Infarction/diagnosis ; Myocardial Infarction/physiopathology ; Myocardial Infarction/prevention & control ; Prognosis ; Protective Factors ; Risk Assessment ; Risk Reduction Behavior ; Stroke Volume ; Time Factors ; Ventricular Function, Left ; Waist Circumference ; Weight Loss
References:
Control Clin Trials. 2003 Oct;24(5):610-28. (PMID: 14500058)
N Engl J Med. 2017 Apr 13;376(15):1407-1418. (PMID: 28402770)
J Am Heart Assoc. 2018 Nov 20;7(22):e010512. (PMID: 30554548)
JACC Heart Fail. 2018 Aug;6(8):640-649. (PMID: 30007558)
J Cardiovasc Magn Reson. 2016 May 31;18(1):32. (PMID: 27245154)
Arch Intern Med. 2010 Sep 27;170(17):1566-75. (PMID: 20876408)
Circulation. 2020 Apr 21;141(16):1295-1306. (PMID: 32134326)
J Am Heart Assoc. 2017 Jul 19;6(7):. (PMID: 28724650)
Diabetes Care. 2007 Jun;30(6):1374-83. (PMID: 17363746)
JACC Heart Fail. 2017 May;5(5):367-374. (PMID: 28396043)
N Engl J Med. 2013 Jul 11;369(2):145-54. (PMID: 23796131)
BMJ. 2018 Jul 3;362:k2575. (PMID: 29970408)
Diabetes Care. 2007 Oct;30(10):2679-84. (PMID: 17644623)
Circ Heart Fail. 2018 Nov;11(11):e005629. (PMID: 30571193)
Int J Obes (Lond). 2008 May;32(5):780-7. (PMID: 18227843)
Circulation. 2016 Feb 16;133(7):639-49. (PMID: 26746176)
Int J Obes (Lond). 2011 Sep;35(9):1241-6. (PMID: 21224826)
JACC Heart Fail. 2018 Dec;6(12):975-982. (PMID: 30497652)
Am Heart J. 1982 Mar;103(3):363-73. (PMID: 7064770)
JACC Heart Fail. 2018 Dec;6(12):999-1007. (PMID: 30316935)
Circ Cardiovasc Imaging. 2013 Sep;6(5):800-7. (PMID: 23929898)
JAMA. 2019 Oct 1;322(13):1271-1282. (PMID: 31475297)
Diabetes Res Clin Pract. 2019 Nov;157:107843. (PMID: 31518657)
Am Heart J. 1976 Jul;92(1):39-46. (PMID: 961576)
Circ Heart Fail. 2012 Mar 1;5(2):152-9. (PMID: 22271752)
N Engl J Med. 2018 Sep 20;379(12):1107-1117. (PMID: 30145941)
Metab Syndr Relat Disord. 2010 Feb;8(1):15-20. (PMID: 19929598)
Am J Clin Nutr. 2005 May;81(5):1018-25. (PMID: 15883424)
Lancet Diabetes Endocrinol. 2014 Oct;2(10):801-9. (PMID: 25127483)
J Cardiopulm Rehabil Prev. 2020 Sep;40(5):302-309. (PMID: 32796492)
N Engl J Med. 2018 Aug 16;379(7):633-644. (PMID: 30110583)
Diab Vasc Dis Res. 2006 Dec;3(3):202-15. (PMID: 17160917)
Obesity (Silver Spring). 2015 Mar;23(3):565-72. (PMID: 25707379)
Br J Nutr. 2017 Nov;118(10):858-866. (PMID: 29110742)
JACC Cardiovasc Imaging. 2021 Feb;14(2):482-494. (PMID: 32305476)
Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921. (PMID: 27595918)
JACC Heart Fail. 2018 Dec;6(12):1008-1010. (PMID: 30316933)
Grant Information:
U01 DK057151 United States DK NIDDK NIH HHS; U01 DK057154 United States DK NIDDK NIH HHS; U01 DK056992 United States DK NIDDK NIH HHS; U01 DK057182 United States DK NIDDK NIH HHS; U01 DK057002 United States DK NIDDK NIH HHS; U01 DK057177 United States DK NIDDK NIH HHS; M01 RR001066 United States RR NCRR NIH HHS; U01 DK057078 United States DK NIDDK NIH HHS; R01 AG045551 United States AG NIA NIH HHS; U01 DK057008 United States DK NIDDK NIH HHS; U01 DK057149 United States DK NIDDK NIH HHS; M01 RR001346 United States RR NCRR NIH HHS; P30 DK048520 United States DK NIDDK NIH HHS; U01 DK057135 United States DK NIDDK NIH HHS; UL1 RR024153 United States RR NCRR NIH HHS; K23 DK124578 United States DK NIDDK NIH HHS; P30 DK046204 United States DK NIDDK NIH HHS; M01 RR002719 United States RR NCRR NIH HHS; M01 RR000056 United States RR NCRR NIH HHS; U01 DK057219 United States DK NIDDK NIH HHS; U01 DK057171 United States DK NIDDK NIH HHS; R03 AG067960 United States AG NIA NIH HHS; R01 AG018915 United States AG NIA NIH HHS; P30 DK072476 United States DK NIDDK NIH HHS; U54 GM104940 United States GM NIGMS NIH HHS; U01 DK057136 United States DK NIDDK NIH HHS; U01 DK057131 United States DK NIDDK NIH HHS; M01 RR000051 United States RR NCRR NIH HHS; T32 HL125247 United States HL NHLBI NIH HHS; U01 DK056990 United States DK NIDDK NIH HHS; UL1 RR025758 United States RR NCRR NIH HHS; U01 DK057178 United States DK NIDDK NIH HHS
Contributed Indexing:
Keywords: heart failure; myocardial infarction; type 2 diabetes mellitus
Molecular Sequence:
ClinicalTrials.gov NCT00017953
Entry Date(s):
Date Created: 20201109 Date Completed: 20211206 Latest Revision: 20211223
Update Code:
20240105
PubMed Central ID:
PMC8366747
DOI:
10.1161/CIRCULATIONAHA.120.050941
PMID:
33164570
Czasopismo naukowe
Background: Intentional weight loss is associated with lower risk of heart failure (HF) and atherosclerotic cardiovascular disease among patients with type 2 diabetes. However, the contribution of baseline measures and longitudinal changes in fat mass (FM), lean mass (LM), and waist circumference (WC) to the risk of HF and myocardial infarction (MI) in type 2 diabetes is not well established.
Methods: Adults from the Look AHEAD trial (Action for Health in Diabetes) without prevalent HF were included. FM and LM were predicted using validated equations and compared with dual-energy x-ray absorptiometry measurements in a subgroup. Adjusted Cox models were used to evaluate the associations of baseline and longitudinal changes in FM, LM, and WC over 1- and 4-year follow-up with risk of overall HF, HF with preserved ejection fraction (EF; EF ≥50%), HF with reduced EF (EF <50%), and MI.
Results: Among 5103 participants, there were 257 incident HF events over 12.4 years of follow-up. Predicted and measured FM/LM were highly correlated ( R 2 =0.87-0.90; n=1369). FM and LM decreased over 4-year follow-up with greater declines in the intensive lifestyle intervention arm. In adjusted analysis, baseline body composition measures were not significantly associated with HF risk. Decline in FM and WC, but not LM, over 1 year were each significantly associated with lower risk of overall HF (adjusted hazard ratio per 10% decrease in FM, 0.80 [95% CI, 0.68-0.95]; adjusted hazard ratio per 10% decrease in WC, 0.77 [95% CI, 0.62-0.95]). Decline in FM was significantly associated with lower risk of both HF subtypes. In contrast, decline in WC was significantly associated with lower risk of HF with preserved EF but not HF with reduced EF. Similar patterns of association were observed for 4-year changes in body composition and HF risk. Longitudinal changes in body composition were not significantly associated with risk of MI.
Conclusions: In adults with type 2 diabetes, a lifestyle intervention is associated with significant loss of FM and LM. Declines in FM and WC, but not LM, were each significantly associated with lower risk of HF but not MI. Furthermore, decline in WC was significantly associated with lower risk of HF with preserved EF but not HF with reduced EF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00017953.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies